InspireMD, Inc. (NYSE:NSPR) CEO Marvin Slosman Acquires 10,330 Shares

Key Points

• CEO Marvin Slosman of InspireMD, Inc. acquired 10,330 shares of the company's stock at an average price of $2.42, increasing his total holdings to 2,420,866 shares.
• InspireMD's stock has a 52-week range of $1.99 to $3.80, with a current price of $2.69 and a market capitalization of $82.41 million.
• Notable institutional investors, including Renaissance Technologies and Northern Trust Corp, have recently increased their stakes in InspireMD, contributing to institutional ownership of 44.78%.

InspireMD, Inc. (NYSE:NSPR - Get Free Report) CEO Marvin Slosman acquired 10,330 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The shares were bought at an average price of $2.42 per share, with a total value of $24,998.60. Following the completion of the purchase, the chief executive officer owned 2,420,866 shares in the company, valued at $5,858,495.72. This trade represents a 0.43% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

InspireMD Stock Performance

NYSE:NSPR traded down $0.10 during trading hours on Friday, reaching $2.69. The stock had a trading volume of 91,579 shares, compared to its average volume of 102,997. InspireMD, Inc. has a 52 week low of $1.99 and a 52 week high of $3.80. The company has a 50 day moving average price of $2.42 and a two-hundred day moving average price of $2.61. The stock has a market capitalization of $82.41 million, a PE ratio of -3.59 and a beta of 0.57.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NSPR. Renaissance Technologies LLC bought a new position in shares of InspireMD during the 4th quarter valued at approximately $27,000. Northern Trust Corp raised its holdings in InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company's stock valued at $126,000 after buying an additional 24,452 shares during the period. Schonfeld Strategic Advisors LLC raised its holdings in InspireMD by 153.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company's stock valued at $79,000 after buying an additional 18,233 shares during the period. Parkman Healthcare Partners LLC increased its position in InspireMD by 721.2% during the fourth quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company's stock valued at $2,248,000 after acquiring an additional 750,635 shares during the last quarter. Finally, Courier Capital LLC purchased a new stake in shares of InspireMD in the first quarter valued at $81,000. 44.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on NSPR shares. Wall Street Zen started coverage on InspireMD in a research note on Monday, May 5th. They issued a "sell" rating for the company. Piper Sandler dropped their price target on InspireMD from $4.50 to $4.00 and set an "overweight" rating for the company in a research note on Monday, May 12th.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.